Loading...
Loading...
Also known as: Quercetin Dihydrate, Quercetin Phytosome
A ubiquitous flavonoid with senolytic, anti-inflammatory, and antiviral properties — a key component of the dasatinib + quercetin senolytic protocol.
Quercetin is one of the most abundant dietary flavonoids, found in onions, apples, berries, and green tea. Beyond its antioxidant properties, it has gained significant attention as a senolytic agent — particularly in combination with dasatinib.
In the D+Q (dasatinib + quercetin) senolytic protocol, quercetin targets senescent endothelial cells while dasatinib handles fat cell progenitors. This combination was the first senolytic cocktail tested in humans.
Standard quercetin has poor absorption (~2%). Phytosome and liposomal forms significantly improve bioavailability (up to 20x for quercetin phytosome).
Quercetin inhibits PI3K, serpins, and BCL-2 family pro-survival proteins in senescent cells. As an antioxidant, it scavenges ROS directly and upregulates endogenous antioxidant enzymes. Its zinc ionophore activity facilitates zinc transport across cell membranes.
Typical Dose
500-1000mg
Frequency
Daily or intermittent senolytic dosing
Cycle Length
Ongoing
Half-Life
~11-28 hours
Extensively studied. GRAS status. First senolytic combination (D+Q) tested in humans. Thousands of published studies.
Very safe at supplemental doses. Rare: headache, GI discomfort. May interact with antibiotics (fluoroquinolones) and blood thinners. High doses may affect thyroid function. Phytosome form recommended for absorption.
An mTOR inhibitor and FDA-approved immunosuppressant being investigated as the most promising pharmacological intervention for extending lifespan.
A direct NAD+ precursor that restores declining cellular energy metabolism and activates sirtuins for anti-aging effects.
The world's most prescribed diabetes drug, now being studied as a potential anti-aging intervention in the landmark TAME clinical trial.